Doxorubicin peptide conjugate - Burnham/ILEX

Drug Profile

Doxorubicin peptide conjugate - Burnham/ILEX

Alternative Names: THP-Dox

Latest Information Update: 06 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial sources
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Drug conjugates; Small molecules
  • Mechanism of Action Integrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 04 May 1998 ILEX Oncology has licensed doxorubicin peptide conjugate from The Burnham Institute
  • 16 Jan 1998 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top